Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Parkinson's patients try brain-boosting balance training to improve walking

NCT ID NCT05799690

Knowledge-focused Sponsor: Prof. Massimo Filippi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding action observation and motor imagery (watching and imagining exercises) to standard dual-task gait training can improve walking and balance in people with Parkinson's disease who have trouble with posture and walking. 80 participants will be randomly assigned to one of two training groups, and researchers will use brain scans and blood tests to look for biomarkers that predict who responds best. The goal is to find better ways to personalize rehabilitation for Parkinson's patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
gait and balance training with dual-task plus action observation and motor imagery
What this could lead to
If successful, this could lead to more personalized rehabilitation programs for Parkinson's patients with walking and balance problems, potentially improving their mobility and quality of life.
What could go wrong
This is a small, early-stage study (80 participants) focused on finding biomarkers, not proving a treatment works. Results may not apply to all Parkinson's patients, and the training requires significant time and effort.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria for PD patients: * 45 years ≤ age ≤ 85 years; * Idiopathic PD according to the Movement Disorders Society (MDS) diagnostic criteria * Hoehn \& Yahr (H\&Y) score \<= 4 * PIGD phenotype * Stable dopaminergic medication for at least 4 weeks and without any changes during the observation period (28 weeks) * No dementia according to Litvan's criteria and Mini-Mental Status Examination score (MMSE) \>= 24 * No significant tremor/involuntary movements that could determine artifacts during the MRI acquisition * Oral and written informed consent to study participation Inclusion criteria for healthy controls: * sex-matched and age-matched (age range: mean age of PD years ± 15 years); * oral and written informed consent to study participation Exclusion criteria: * Medical conditions or substance abuse that could interfere with cognition; * Any major systemic, psychiatric, neurological, visual, and musculoskeletal disturbances or other causes of walking inability; * Contraindications to undergoing MRI examination; * Brain damage at routine MRI, including lacunae and extensive cerebrovascular disorders; * Denied oral and written informed consent to study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease

Contacts and locations

Locations

  • IRCCS San Raffaele

    Milan, 20132, Italy

  • Neurology Unit, Azienda Ospedaliera Universitaria Integrata di Verona

    Verona, 37126, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.